Aktienanalyse zu GlucoTrack Inc (GCTK)GCTKGlucoTrack Inc

Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

GlucoTrack Inc is not a good buy right now due to significant financial losses and a very low stock price. The current price is $0.40, which reflects a staggering 99.31% decline year-to-date. The company's forward P/E ratio is 0, indicating no expected earnings growth, and the RSI is at 8.128, suggesting extreme oversold conditions but also a lack of momentum for recovery. The main risk is the company's requirement to maintain a closing bid price of at least $1.00 by November 9, 2026, to avoid delisting from Nasdaq, which adds pressure on the stock.